Setmelanotide vs Semaglutide

Setmelanotide activates MC4R, a hunger-control receptor downstream of leptin, and is approved for rare genetic obesities (such as POMC or LEPR deficiency). Semaglutide acts on GLP-1 receptors and is used in common obesity.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Setmelanotide

A melanocortin-4 receptor agonist approved for rare genetic obesities caused by defects in the leptin–melanocortin pathway.

BEST STUDIED FOR

Melanocortin

Read the cited profile →

🧪

Semaglutide

A long-acting GLP-1 receptor agonist, the reference molecule of the modern incretin era in both injectable and oral form.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Setmelanotide	Semaglutide
The key difference	MC4R agonist for rare genetic obesity	GLP-1 agonist for common obesity
Class	Melanocortin	Incretin & metabolic
Mechanism	MC4R neurons integrate leptin and POMC signals to regulate hunger and energy expenditure.	Semaglutide is a GLP-1 analogue with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin, extending its half-life to about a week.
Status	Approved (2020 onward) for POMC, PCSK1 or LEPR deficiency obesity and Bardet–Biedl syndrome; studied in hypothalamic obesity.	Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa.
Reported safety signals	Trials report injection-site reactions and skin hyperpigmentation (an expected MC1R effect), with nausea early in treatment.	Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping.
A key study	Summarises setmelanotide’s development and first approval for POMC, PCSK1 or LEPR deficiency obesity. (Drugs 2021, PMID 33638809)	Reviews the safety profile of semaglutide across subcutaneous and oral formulations. (Front Endocrinol (Lausanne) 2021, PMID 34305810)

WHEN TO RESEARCH WHICH

Setmelanotide targets a specific broken pathway; semaglutide a general satiety pathway. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Setmelanotide] Setmelanotide: First Approval — Drugs 2021. PMID 33638809
[Setmelanotide] Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials — Lancet Diabetes Endocrinol 2020. PMID 33137293
[Setmelanotide] Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period — Lancet Diabetes Endocrinol 2022. PMID 36356613
[Semaglutide] Safety of Semaglutide — Front Endocrinol (Lausanne) 2021. PMID 34305810
[Semaglutide] A systematic review of the effect of semaglutide on lean mass: insights from clinical trials — Expert Opin Pharmacother 2024. PMID 38629387
[Semaglutide] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — JAMA 2021. PMID 33755728

FREQUENTLY ASKED

What is the difference between Setmelanotide and Semaglutide?

What is the regulatory status of Setmelanotide and Semaglutide?

Setmelanotide: Approved (2020 onward) for POMC, PCSK1 or LEPR deficiency obesity and Bardet–Biedl syndrome; studied in hypothalamic obesity. Semaglutide: Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa.

What safety signals have been reported?

Setmelanotide: Trials report injection-site reactions and skin hyperpigmentation (an expected MC1R effect), with nausea early in treatment. Semaglutide: Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping.

Which studies is this comparison based on?

For Setmelanotide: “Setmelanotide: First Approval” (PMID 33638809); “Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials” (PMID 33137293); “Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period” (PMID 36356613). For Semaglutide: “Safety of Semaglutide” (PMID 34305810); “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials” (PMID 38629387); “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial” (PMID 33755728).